A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer (NCT03473743)
A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects With Metastatic or Locally Advanced Urothelial Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to: (a) characterize the safety and tolerability of and to identify the recommended Phase 2 dose (RP2D) and schedule for erdafitinib in combination with cetrelimab, and for erdafitinib in combination with cetrelimab and platinum (cisplatin and carboplatin) chemotherapy and; (b) to evaluate the safety and clinical activity of erdafitinib alone and in combination with cetrelimab in cisplatin-ineligible participants with metastatic or locally advanced urothelial cancer (UC) with select fibroblast growth factor receptor (FGFR) gene alterations and no prior systemic therapy for metastatic disease.
Who can join: Review the eligibility criteria below.
Location: Rocky Mountain Cancer Centers — Aurora, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (127 Sites)
Showing the first 25 of 127 sites.
- Rocky Mountain Cancer Centers — Aurora, Colorado
- Norton Cancer Institute — Louisville, Kentucky
- Maryland Oncology Hematology, PA — Rockville, Maryland
- Hackensack University Medical Center — Hackensack, New Jersey
- Weill Cornell Medical College - NY Presbyterian Hospital — New York, New York
- White Plains Hospital Center for Cancer Care — White Plains, New York
- Levine Cancer Institute, Carolinas HealthCare System — Charlotte, North Carolina
- Toledo Clinic Cancer Centers — Toledo, Ohio
- Penn State Hershey Cancer Institute — Hershey, Pennsylvania
- Texas Oncology, P.A. — Fort Worth, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Virginia Oncology Associates — Norfolk, Virginia
- Brest Regional Oncology Dispensary — Brest,
- Grodno University Hospital — Grodno,
- Gomel Regional Clinical Oncology Dispensary — Homyel,
- State Institution N.N. Alexandrov Republican Scientific and — Lesnoy,
- Minsk city Clinical Oncological Dispensary — Minsk,
- Mogilev Regional Hospital — Mogilev,
- Vitebsk Regional Clinical Hospital — Vitebsk,
- ULB Hôpital Erasme — Brussels,
- Cliniques Universitaires Saint Luc — Brussels,
- Jolimont — Haine-Saint-Paul,
- Az Groeninge — Kortrijk,
- CHU de Liège - Domaine Universitaire du Sart Tilman — Liège,
- AZ Nikolaas - Campus Sint-Niklaas Moerland — Sint-Niklaas,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Urothelial Carcinoma
- Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) — Springdale, Arkansas
- Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma — Philadelphia, Pennsylvania
- A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma — Houston, Texas
- A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder — Bloomington, Indiana
- Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma — Oklahoma City, Oklahoma
- Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC — Tampa, Florida
Explore by condition: All Urothelial Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.